STATIL
STATIL
CAS: 72702-95-5
Molecular Formula: C17H12BrFN2O3
STATIL - Names and Identifiers
STATIL - Physico-chemical Properties
| Molecular Formula | C17H12BrFN2O3 |
| Molar Mass | 391.19 |
| Density | 1.60 |
| Melting Point | 184-186℃ (DEC.) |
| Storage Condition | Store at RT |
| In vitro study | Ponalrestat (ICI 128436; 1, 10, 100 μM; 6 hours) reduces PGF2αproduction in response to IL-1 in both cultured endometrial cells and endometrial explants. |
| In vivo study | Ponalrestat (ICI 128436; 10, 50 mg/kg; orally; daily; 8 weeks) reduces sorbitol accumulation indicating efficacy of aldose reductase inhibition. Animal Model: Adult female Sprague-Dawley rats Dosage: 10, 50 mg/kg Administration: Orally; daily; 8 weeks Result: Reduced sorbitol accumulation. |
STATIL - Risk and Safety
| Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
STATIL - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.556 ml | 12.782 ml | 25.563 ml |
| 5 mM | 0.511 ml | 2.556 ml | 5.113 ml |
| 10 mM | 0.256 ml | 1.278 ml | 2.556 ml |
| 5 mM | 0.051 ml | 0.256 ml | 0.511 ml |
Last Update：2024-01-02 23:10:35
STATIL - Reference Information
| overview | Polaris can be used as an intermediate in pharmaceutical synthesis. If you inhale Boris, please move the patient to fresh air; if you are in contact with the skin, you should remove the contaminated clothes, rinse the skin thoroughly with soapy water and water, and see a doctor if you feel uncomfortable; if you are in contact with the eyes, you should separate the eyelids, Rinse with flowing water or normal saline, and see a doctor immediately; if you eat, rinse your mouth immediately, prohibit vomiting, and see a doctor immediately. |
| Biological activity | Ponalrestat (ICI 128436) is an orally active, selective and non-competitive aldose reductase (aldose reductase;AKR1B1;ALR) inhibitor. Ponalrestat can selectively inhibit ALR2,Ki is 7.7 nM, and the Ki value for ALR1 is 60 μM. Ponalrestat inhibits the conversion of glucose to sorbitol. |
| target | Ki: 7.7 nM (ALR2) and 60 μM (ALR1) |
| in vitro study | Ponalrestat (ICI 128436; 1, 10,100 μM; 6 hours) reduces PGF2αproduction in response to IL-1 in both cultured endometrial cells and endometrial explants. |
| in vivo study | Ponalrestat (ICI 128436; 10, 50 mg/kg; orally; daily; 8 weeks) reduces sorbitol accumulation indicating efficacy of aldose reductase inhibition. Animal Model: Adult female Sprague-Dawley rats Dosage: 10, 50 mg/kg Administration: Orally; daily; 8 weeks Result: reduced sorbitol accumulation. |
| Animal Model: | Adult female Sprague-Dawley rats |
| Dosage: | 10, 50 mg/kg |
| Administration: | Orally; daily; 8 weeks |
| Result: | Reduced sorbitol accumulation. |
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: STATIL Visit Supplier Webpage Request for quotationCAS: 72702-95-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: STATIL Visit Supplier Webpage Request for quotationCAS: 72702-95-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History